Pacific Biosciences posts 2025 preliminary update

Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025.

Filing Impact

(High)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Pacific Biosciences of California, Inc. filed a current report to highlight a business update and unaudited preliminary financial results for the quarter and year ended December 31, 2025. The company issued a press release that includes preliminary revenue estimates and a preliminary balance of cash, cash equivalents and investments as of December 31, 2025.

Portions of the press release that cover these preliminary figures and the forward-looking statements section are treated as filed under the "Other Events" section, while the broader business update and results discussion are furnished under results-of-operations disclosure rules. The company notes that its financial statements for this period are not yet finalized or audited and may change materially, and cautions readers not to place undue reliance on the preliminary information.

8-K Event Classification

3 items: 2.02, 8.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pacific Biosciences (PACB) disclose in this 8-K?

Pacific Biosciences of California, Inc. reported that it issued a press release providing a business update and announcing unaudited preliminary financial results for the quarter and year ended December 31, 2025.

Which financial periods are covered by PACB’s preliminary results?

The unaudited preliminary financial results and related estimates cover Pacific Biosciences’ quarter and full year ended December 31, 2025.

What specific financial information from PACB is incorporated as an "Other Event"?

The information referencing Pacific Biosciences’ expectations for preliminary revenue estimates for the quarter and year ended December 31, 2025, its preliminary cash, cash equivalents and investments balance as of December 31, 2025, and the "Forward-looking statements" paragraph is incorporated into the Other Events section.

Are PACB’s preliminary 2025 results final or audited?

No. The company states that its financial statements for the quarter and year ended December 31, 2025 have not yet been finalized or audited and may change materially from the unaudited preliminary information in the press release.

How is the PACB press release treated for SEC purposes?

The portions of the press release related to preliminary revenue, cash, cash equivalents and investments and forward-looking statements are being filed as an Other Event, while the remaining portions are furnished as results-of-operations disclosure and are not deemed filed under Section 18 of the Exchange Act.

Where can investors find the detailed PACB preliminary figures?

The detailed unaudited preliminary financial information is contained in the press release referenced as Exhibit 99.1 to the report, which is incorporated by reference as described in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 01/12/2026 - 09:07 AM EST

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

January 12, 2026

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)


Delaware	001-34899	16-1590339
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PACB

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On January 12, 2026, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter and year ended December 31, 2025 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 8.01. OTHER EVENTS.

The information set forth in the Press Release, solely to the extent such information references the Company’s expectations for preliminary revenue estimates for the quarter and year ended December 31, 2025 and preliminary cash, cash equivalents and investments balance as of December 31, 2025, together with the paragraph set forth under the heading “Forward-looking statements”, is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.

The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Because the Company’s financial statements as of and for the quarter and year ended December 31, 2025 have not yet been finalized or audited and remain subject to change, the Company’s final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.


(d)			Exhibits.

99.1			Press Release issued by Pacific Biosciences of California, Inc. dated January 12, 2026

104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	Pacific Biosciences of California, Inc.

	By:	/s/ Michele Farmer
		Michele Farmer
		Vice President and Chief Accounting Officer
Date: January 12, 2026

Source: View Original Filing on SEC EDGAR